Sub-classification of patients at increased risk of CIN may allow for improved treatment modifications, such as G-CSF support, dose reduction, or use of chemotherapy regimens with a lower risk of myelosuppression. The gene discussed is CSF3; the disease is cervical squamous intraepithelial neoplasia.